Catherine E. Cooke, PharmD

Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.

This retrospective study found no benefit of a disease management program compared with usual care on utilization of secondary prevention pharmacotherapies in postmyocardial infarction patients.